Ascendis Pharma AS (ASND) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

ASND

132.08

USD-1.59-1.19%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Filings

News

Chart

Latest News

@MarketRebels

STARTS NOW Rebel's Edge 🏴‍☠️ 1pm CME Fed Tool swings to 61% Chance of 50 bps cut. China's economy showing signs of strain. #UOA in $ORCL $AAPL $ASND $NUVL with @MXLESQ Sports 🏈 @petenajarian NFL: Early poor start for great teamsRavens 0-2, Cinci 0-2... why? https://t.co/qlnNHGky8b

Seeking Alpha

3 years

ASND, GDS, ADSK and CDZI among after hours movers

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

130.32USD

134.49USD

52 Week Range

101.43USD

161.00USD

Market Cap

8.15BUSD

Billionaire Owners

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

US04351P1012

CUSIP

04351P101

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

-2.57

Dividend Share

Dividend Yield

Earnings Share

-7.88

Wall Street Target Price

181.9796

EPS Estimate Current Year

-7.1873

EPS Estimate Next Year

-3.3766

EPS Estimate Current Quarter

-1.5153

EPS Estimate Next Quarter

-1.4377

Most Recent Quarter

Profitability

Revenue TTM

317,628,000

Gross Profit TTM

39,037,000

EBITDA

-347,192,992

Profit Margin

-154.12%

Return On Assets TTM

-27.92%

Return On Equity TTM

-818.43%

Revenue Per Share TTM

5.595

Qtly Revenue Growth YOY

-24.00%

Diluted Eps TTM

-7.88

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

25.6471

Price Book MRQ

14.5547

Enterprise Value Revenue

Enterprise Value EBITDA

-20

Peers analysis

BNTXBioNTech SE
117.53
0.32%
ARGXargenx NV ADR
618.81
0.18%
ARGNFargenx SE
525.60
0.00%
CMXHFCSL Limited
173.75
0.00%
UCBJFUCB SA
174.00
0.00%

REGNRegeneron Pharmaceuticals Inc
753.59
-1.19%
VRTXVertex Pharmaceuticals Inc
460.81
-0.99%
CSLLYCSL Ltd
91.00
-0.96%
ALNYAlnylam Pharmaceuticals Inc
251.19
-0.73%
UCBJYUCB SA ADR
97.52
-0.51%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2024